

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sisunatovir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sisunatovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 30, 2023
Lead Product(s) : Sisunatovir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sisunatovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Syncytial Virus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sisunatovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Respiratory Syncytial Virus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 12, 2023
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sisunatovir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Compare Different Preparations of Sisunatovir in Healthy Adult Participants.
Details : Sisunatovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2023
Lead Product(s) : Sisunatovir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sisunatovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Syncytial Virus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 14, 2023
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sisunatovir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.
Details : Sisunatovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 26, 2023
Lead Product(s) : Sisunatovir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants
Details : Sisunatovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Syncytial Viruses.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 03, 2023
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Pfizer Inc
Deal Size : $155.0 million
Deal Type : Collaboration
Details : RV521 (sisunatovir) is an investigational orally administered fusion inhibitor designed to block RSV replication by inhibiting F-mediated fusion with the host cell. Sisunatovir is being evaluated for the potential treatment of RSV infection in pediatric ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $20.0 million
December 19, 2022
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Pfizer Inc
Deal Size : $155.0 million
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Pfizer Inc
Deal Size : $525.0 million
Deal Type : Acquisition
Pfizer Completes Acquisition of ReViral
Details : ReViral brings to Pfizer a portfolio of promising therapeutic candidates, including RV521 (sisunatovir), an orally administered inhibitor designed to block fusion of the RSV virus to the host cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 09, 2022
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Pfizer Inc
Deal Size : $525.0 million
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Pfizer Inc
Deal Size : $525.0 million
Deal Type : Acquisition
Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates
Details : Proposed acquisition strengthens Pfizer’s capabilities in infectious disease research and development with a promising therapeutic candidates, including sisunatovir, an orally administered inhibitor designed to block fusion of the RSV virus to the host...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 07, 2022
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Pfizer Inc
Deal Size : $525.0 million
Deal Type : Acquisition
